Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800226 | 0.90 | NPSR1 (0.38) | NPSR1IMPDH2DHFRCDC7DBF4 | |
| SCHEMBL5807749 | 0.81 | NPSR1 (0.47) | NPSR1CDC7DBF4MAPT | |
| SCHEMBL28323788 | 0.76 | NPSR1 (0.39) | NPSR1IMPDH2CDC7DBF4CYP2D6 | |
| SCHEMBL11208926 | 0.72 | DHFR (0.36) | DHFR | |
| SCHEMBL486583 | 0.69 | CASP1 (0.46) | NPSR1IMPDH2 | |
| SCHEMBL369674 | 0.69 | CASP1 (0.40) | NPSR1IMPDH2 | |
| SCHEMBL4763149 | 0.68 | KDM4E (0.38) | NPSR1MAPTSRD5A1 | |
| SCHEMBL3803757 | 0.68 | NPSR1 (0.42) | NPSR1IMPDH2CDC7DBF4 | |
| SCHEMBL9284251 | 0.68 | NPSR1 (0.55) | NPSR1IMPDH2CDC7DBF4MAPT | |
| SCHEMBL1032160 | 0.68 | KDM4E (0.36) | NPSR1MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644389-B1 | PYRIMIDINE COMPOUNDS HAVING PHOSPHONATE GROUPS AS ANTIVIRAL NUCLEOTIDE ANALOGS | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 2011-01-19 | — | — | EP | disclosed |
| US-20060241081-A1 | Novel compounds and methods for therapy | INSTITUTE OF ORGANIC CHEMISTRY | 2006-10-26 | — | — | US | disclosed |
| US-7115592-B2 | Phosphonate substituted pyrimidine compounds and methods for therapy | INSTITUTE OF ORGANIC CHEMISTRY (CZ) | 2006-10-03 | — | — | US | disclosed |
| EP-1644389-A1 | PYRIMIDINE COMPOUNDS HAVING PHOSPHONATE GROUPS AS ANTIVIRAL NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-04-12 | — | — | EP | disclosed |
| US-20050075318-A1 | Novel compounds and methods for therapy | INSTITUTE OF ORGANIC CHENISTRY AND BIOCHEMISTRY ACADEMYOF SCIENCES OF THE CZECH REPUBLIC | 2005-04-07 | — | — | US | disclosed |
| WO-2004111064-A1 | PYRIMIDINE COMPOUNDS HAVING PHOSPHONATE GROUPS AS ANTIVIRAL NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075318-A1 | Novel compounds and methods for therapy | ZC3HAV1, IFNAR1, EIF2AK2 | NPSR1 2453/4885IMPDH2 512/4885DHFR 72/4885 |
| US-20060241081-A1 | Novel compounds and methods for therapy | ZC3HAV1, IFNAR1, EIF2AK2 | NPSR1 2453/4885IMPDH2 512/4885DHFR 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.